Literature DB >> 1487315

Pneumocystis carinii induction of tumor necrosis factor-alpha by alveolar macrophages: modulation by pentamidine isethionate.

E Corsini1, C Dykstra, W A Craig, R R Tidwell, G J Rosenthal.   

Abstract

Pneumocystis carinii, and the inflammatory response it provokes, together contribute to irreversible lung damage in immunocompromised patients. P. carinii cysts were found to be capable of inducing tumor necrosis factor-alpha (TNF) release from alveolar macrophages in a concentration-dependent manner. At physiologically achievable concentrations, pentamidine isethionate (pentamidine) substantially reduces such production. Pretreatment of alveolar macrophages (AM phi) with interferon-gamma (IFN-gamma) synergizes with P. carinii to produce increased levels of TNF, a condition which pentamidine was also able to antagonize. Pentamidine treatment did not interfere with the phagocytic ability of AM phi. Considering clinical reduction of TNF could lessen P. carinii pneumonia (PCP) induced inflammation, the efficacy of pentamidine in the treatment of PCP may be partially associated with its ability to inhibit the release of inflammatory mediators such as TNF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1487315     DOI: 10.1016/0165-2478(92)90228-g

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  3 in total

1.  Pentamidine blocks hepatotoxic injury in mice.

Authors:  Enpeng Zhao; Ghulam Ilyas; Francesca Cingolani; Jae Ho Choi; François Ravenelle; Kathryn E Tanaka; Mark J Czaja
Journal:  Hepatology       Date:  2017-07-20       Impact factor: 17.425

2.  Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms.

Authors:  J F Downing; D L Kachel; R Pasula; W J Martin
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

3.  Pentamidine Alleviates Inflammation and Lipopolysaccharide-Induced Sepsis by Inhibiting TLR4 Activation via Targeting MD2.

Authors:  Siru Wu; Cong Lin; Tianshu Zhang; Bo Zhang; Yushan Jin; Hongshuang Wang; Hongyuan Li; Yibo Wang; Xiaohui Wang
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.